At the State University of Penza, researchers developed analogs containing synthetic components based on a buckwheat extract associated with Redstein, preserving its robust properties. A report describing these findings circulated to the Russian Ministry of Education and Science.
There are many medicines for preventing and treating inflammation and easing pain. In recent years, scientists have looked to develop plant-derived therapies, including expanding the use of buckwheat-based components, due to the risk of side effects from long-term use of some drugs, such as rashes, itching, or eczema.
Researchers proposed using an annual plant at PSU known as red buckwheat, Fagopyrum rubricraulis. It accumulates a wide range of phenolic compounds and flavonoids. The above-ground parts contain rutin, quercetin, izokvercetin, orientin, isoorientin, and isovitexin. In addition, chlorogenic acid, caffeic acid, catechins, and tannins have been found. All of these substances exhibit anti-inflammatory, analgesic, antimicrobial and regenerative effects.
Experts developed laboratory samples in a soft dosage form for topical use based on Red-Standard buckwheat extract. To obtain a dry extract, all above-ground parts are collected: leaves, flowers and stems. Buckwheat should be harvested during the flowering phase, from late July to early August. For the new drug, the concentration should be 10 percent of plant material extraction, and at this level a meaningful pharmacological effect is achieved.
As the gel-forming base, the researchers chose the sodium salt of carboxymethyl cellulose. It is compatible with the dosage form’s components, gentle on the skin and unlikely to cause adverse effects.
Experiments showed that a phytopreparation based on red buckwheat extract, when applied as a gel to damaged skin, produced a pronounced anti-inflammatory response.
Earlier studies described the links between intestinal microbiota and mood, noting that gut bacteria can influence depressive states.